A retrospective chart review study of recombinant factor IX albutrepenonacog alfa treatment in previously untreated pediatric patients with hemophilia B in Japan - A retrospective chart review study of recombinant factor IX albutrepenonacog alfa treatment in previously untreated pediatric patients with hemophilia B in Japan

CSL Behring K.K.0 个研究点目标入组 24 人开始时间: 2024年2月28日最近更新: 2024年5月27日

适应症

试验速览

暂无简介。

•1) Participating in any interventional clinical trials during the period between 1 May 2017 and 30 June 2024. If patients discontinue rIX-FP during the period above, patients who participated in any interventional clinical trials during the period between 1 May 2017 and the date of discontinuation will be excluded from the study. * Treatment discontinuation is defined as: (1) a switch to other FIX products (excluding a temporary switch defined as <3 doses of other FIX products/<1 month duration of other FIX products) and (2) loss to follow up due to transfer to a different hospital, death, or other reasons. The date of discontinuation is defined as (1) the date of a switch to other FIX products, (2)the date of transfer to a different hospital, the date of death, or the date of loss to follow-up confirmed by the investigator. 2) Patients who have previously treated with other FIX product(s) before initiation of rIX-FP 3) Patients enrolled in rIX-FP post-marketing surveillance (PMS)

发起方